OnKure net loss narrows to $15.2 million in Q1 2026

OnKure Therapeutics, Inc. Class A

OnKure Therapeutics, Inc. Class A

OKUR

0.00
  • OnKure Therapeutics posted a net loss of $15.2 million, or $1.11 per share, for first-quarter 2026, narrowing from a $15.9 million loss a year earlier.
  • R&D expense fell 10% to $11.7 million, while G&A expense edged down to $3.9 million.
  • Cash and cash equivalents climbed to $192.1 million as of March 31, following a $150 million private placement that closed the same day.
  • OKI-355 was nominated as lead vascular anomalies candidate, OKI-345 was selected for breast cancer, with IND submissions for both planned in first-half 2027.
  • OnKure said it is not planning to independently pursue further clinical development of OKI-219, with data from PIKture-01 expected by end of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onkure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605051605PRIMZONEFULLFEED9712549) on May 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.